Plus Therapeutics Names Randy Goodman as VP, Grants 9,000 Shares at $5.41 Strike
Plus Therapeutics named Randy H. Goodman, Ph.D., MHA as Vice President, Value Strategy & HEOR on April 13, 2026 to lead market access for CNSide and REYOBIQ. He received 9,000 inducement shares: 4,500 options at $5.41 strike vesting over four years and 4,500 RSUs vesting over three years.
1. Leadership Appointment
Plus Therapeutics appointed Randy H. Goodman, Ph.D., MHA as Vice President, Value Strategy & Health Economics and Outcomes Research effective April 13, 2026. Dr. Goodman brings over 20 years of global pricing, reimbursement strategy, real-world evidence generation and value-based healthcare modeling experience across biotechnology, pharmaceuticals, diagnostics and medical devices.
2. Market Access and Value Strategy Role
In his new position, Dr. Goodman will spearhead market access, payer engagement and reimbursement frameworks for the CNSide Diagnostics platform and the REYOBIQ radiotherapeutic pipeline. His expertise in health policy and value demonstration is expected to strengthen payer and provider adoption strategies.
3. Inducement Equity Grant Details
As an inducement to join the company, Dr. Goodman was granted 9,000 shares under the 2015 New Employee Incentive Plan: 4,500 stock options at a $5.41 exercise price vesting over four years and 4,500 restricted stock units vesting over three years. These awards comply with Nasdaq Rule 5635(c)(4) and are subject to continued service through each vesting date.